S-Sibutramine metabolite - Sepracor

Drug Profile

S-Sibutramine metabolite - Sepracor

Alternative Names: (-)-DDMS; (-)-didesmethylsibutramine - Sepracor; (S)-didesmethylsibutramine - Sepracor; (S)-Sibutramine metabolite - Sepracor; S-DDMS; S-desmethylsibutramine - Sepracor; S-didesmethylsibutramine - Sepracor

Latest Information Update: 27 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sepracor
  • Class
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Female sexual dysfunction; Male sexual dysfunction

Most Recent Events

  • 27 Jun 2006 No development reported - Phase-I for Female sexual dysfunction in USA (unspecified route)
  • 27 Jun 2006 No development reported - Phase-II for Male sexual dysfunction in USA (unspecified route)
  • 04 Oct 2001 Phase-I clinical trials for Female sexual dysfunction in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top